Loading
KalVista Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Venrock Healthcare Capital Partners III, L.P., was filed 11 Apr 2025.
Insider Decl.
499
Thresholds
n/a
Buy Volume
€48M
48 ops. · all time
Sell Volume
€79M
278 ops. · all time
Who traded when
BuySaleBenjamin L. Palleiko20 sales
Paul K. Audhya17 sales
Christopher Yea15 sales
Venrock Healthcare Capital Partners III, L.P.9 buys5 sales
Nicole Sweeny5 sales
Brian Piekos3 sales
Analyst consensus: bullish or bearish?
Analysts rate KalVista Pharmaceuticals, Inc. Hold (neutral), based on 3 analysts. Average price target: US$27.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$27.00
Analyst consensus
3 analystsHold
US$27.00Target US$27.00(0%)US$27.00
Income statement
RevenueUS$10.9M
EBITDA-US$173.3M-1586% margin
Net income-US$183.4M-118.7% margin
Valuation
PER (forward)17.5x
Beta-0.11
Balance sheet & cash
Market capUS$1.4B
Total debtUS$151.6M
Free Cash Flow-US$153.8M
Profitability & ownership
% insiders1.7%
% institutions136.9%
Last declaration on 11 June 2026
Declarations499 total
150,260 sharesCommon StockSEC:0001860131-26-000010:0
2,239 shares@ US$26.77780.0036% mcap10.9% of flowCommon StockSEC:0001860131-26-000008:1
5,000 sharesCommon StockSEC:0001860131-26-000008:0
2,685 shares@ US$26.78440.0043% mcap13.1% of flowCommon StockSEC:0001860131-26-000007:1
6,250 sharesCommon StockSEC:0001860131-26-000007:0
9,550 shares@ US$20.21630.013% mcap22.2% of flowCommon StockSEC:0001366244-26-000006:1
1,862 shares@ US$20.21630.0025% mcap100.0% of flowCommon StockSEC:0001827505-26-000003:1
2,686 shares@ US$20.21630.0037% mcap9.7% of flowCommon StockSEC:0001860131-26-000004:1
1,862 shares@ US$20.21630.0025% mcap100.0% of flowCommon StockSEC:0001815308-26-000003:1
6,250 sharesCommon StockSEC:0001860131-26-000004:0
20,312 sharesCommon StockSEC:0001366244-26-000006:0
6,250 sharesCommon StockSEC:0001815308-26-000003:0
6,250 sharesCommon StockSEC:0001827505-26-000003:0
160 shares@ US$17.530.0% of flowCommon StockSEC:0001231919-26-000286:1
21,386 shares@ US$17.761.6% of flowCommon StockSEC:0001231919-26-000286:2
15,417 shares@ US$18.821.2% of flowCommon StockSEC:0001231919-26-000286:3
3,183 shares@ US$19.120.2% of flowCommon StockSEC:0001231919-26-000286:4
174,485 shares@ US$16.9527.7% of flowCommon StockSEC:0001231919-26-000286:0
6,693 shares@ US$16.081.9% of flowCommon StockSEC:0001366244-26-000005:1
15,625 sharesCommon StockSEC:0001366244-26-000005:0
3,125 sharesCommon StockSEC:0001691102-26-000002:1
5,000 sharesCommon StockSEC:0001827505-26-000002:1
5,000 sharesCommon StockSEC:0001860131-26-000003:1
4,347 shares@ US$15.571.7% of flowCommon StockSEC:0001691102-26-000002:2
3,975 shares@ US$15.5731.3% of flowCommon StockSEC:0001827505-26-000002:2
25 of 499 declarations
About KalVista Pharmaceuticals, Inc.
On October 12, 2017, three KalVista Pharmaceuticals, Inc. filers bought together for EUR 16,324,828, the densest buying window in the record. RA Capital Management, LLC and Rajeev M. Shah (both Director) each reported EUR 6,106,425 that day. The largest single purchase is Albert Cha's (Director), at EUR 15,522,668 on September 10, 2018.
Sales are more numerous: 278 worth EUR 79.4 million (median EUR 52,796), against 49 purchases worth EUR 54.2 million (median EUR 367,256). The biggest come from 10% owners: Venrock Healthcare Capital Partners II, L.P. with EUR 12,699,019 on March 18, 2019, Novo Holdings A/S with EUR 12,399,635 on October 12, 2017, and SVLSF IV, LLC with EUR 6,019,981 on March 18, 2019.
Read moreShow less
This US healthcare company, valued at USD 1.4 billion, has 499 filings from 24 filers, including 140 option exercises and 23 grants. Christopher Yea (Chief Development Officer) is the most frequent, with 89 filings. The year 2019 has 92, against 7 in 2018. Over the last twelve months: 65 filings, 31 sales and no purchase. They are published a median of 2 days after the trade.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
